Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Krystal Biotech
Special Reports
10 top M&A targets in biotech for 2023
After a slow 2022, will we see a return to form for biopharma M&A? And, if so, which biotechs does Big Pharma have in its sight? Here are our predictions.
James Waldron
,
Annalee Armstrong
,
Nick Paul Taylor
Jan 30, 2023 3:00am
Krystal Biotech eyes phase 3 for rare skin disease gene therapy
Jun 24, 2019 11:13am
Novartis farms out rare disease drug to LifeMax Labs
Aug 27, 2018 10:30am
Krystal files for IPO to move gene therapies into clinic
Aug 22, 2017 10:23am
